Reactivation of retinopathy of prematurity: current aspects and unsolved problems—a review
Russian Medicine · 05.07.2026 · 32 (3) · 262-270
DOI: 10.17816/medjrf702716 ↗Kurz gefasst
Fachartikel in der Zeitschrift Russian Medicine, online erschienen am 05.07.2026. Verfasst von Serg V. Lesovoy und 5 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben.
Abstract (Originalsprache)
Due to advances in modern neonatology in the care of extremely premature infants in economically developed countries, including Russia, retinopathy of prematurity (ROP) and its consequences continue to represent a significant proportion of ophthalmic pathologies of early childhood. Thus, as the number of extremely immature premature infants increases, so does the number of severe, rapidly progressing forms of ROP localized to the central fundus (zone I ROP and aggressive posterior ROP) that are resistant to laser coagulation. In recent decades, intravitreal injection of anti-VEGF agents (VEGF, vascular endothelial growth factor) has been a primary treatment modality for ROP. The purpose of this review is to systematically review studies on ROP reactivation. Risk factors for ROP reactivation, its frequency, and its dependence on the choice of treatment strategy are discussed. The effectiveness of all commonly used anti-VEGF agents worldwide is analyzed comparatively in relation to the development of signs of ROP reactivation, including dosage- and duration-dependent effects. An important part of this review discusses the time course of ROP reactivation, since clear criteria for differentiating this timing have not yet been established. We also address long-term retinal changes in the cicatricial phase of the disease, which are clinically similar to those seen in active retinopathy and involve tractional-exudative changes at the borders of persistent avascular zones, as well as approaches to treatment, including preventive measures. The review demonstrates an association between an increased frequency of ROP reactivation following anti-VEGF therapy, underscoring the need to develop new approaches to long-term follow-up of these patients. The prolongation of possible reactivation periods due to repeated anti-VEGF injections to achieve ROP regression should proportionally extend the duration of follow-up for these patients, especially when avascular zones persist in the retina.
Zitieren
APA
Lesovoy, S. V., Krivovyaz, O. S., Kuznetsova, Y. D., Bogomolova, E. A., Salmasi, J. M., & Balashova, L. M. (2026). Reactivation of retinopathy of prematurity: current aspects and unsolved problems—a review. Russian Medicine, 32(3), 262-270. https://doi.org/10.17816/medjrf702716
Vancouver
Lesovoy SV, Krivovyaz OS, Kuznetsova YD, Bogomolova EA, Salmasi JM, Balashova LM. Reactivation of retinopathy of prematurity: current aspects and unsolved problems—a review. Russian Medicine. 2026;32(3):262-270. doi:10.17816/medjrf702716
BibTeX
@article{Lesovoy2026,
author = {Lesovoy, Serg V. and Krivovyaz, Olga S. and Kuznetsova, Yuliya D. and Bogomolova, Ekaterina A. and Salmasi, Jean M. and Balashova, Larisa M.},
title = {Reactivation of retinopathy of prematurity: current aspects and unsolved problems—a review},
journal = {Russian Medicine},
year = {2026},
volume = {32},
number = {3},
pages = {262--270},
doi = {10.17816/medjrf702716}
}
EUVIMED